MiMedx Group, Inc. (NASDAQ:MDXG) CEO Joseph H. Capper Purchases 200,000 Shares

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) CEO Joseph H. Capper purchased 200,000 shares of MiMedx Group stock in a transaction on Friday, May 2nd. The stock was bought at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the completion of the acquisition, the chief executive officer now owns 529,530 shares in the company, valued at $3,357,220.20. The trade was a 60.69 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

MiMedx Group Trading Down 4.0 %

Shares of MiMedx Group stock traded down $0.30 on Friday, reaching $7.12. The company had a trading volume of 1,111,673 shares, compared to its average volume of 695,530. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of 12.95 and a beta of 1.85. The firm's 50-day moving average price is $7.28 and its two-hundred day moving average price is $8.11. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. As a group, research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 target price on shares of MiMedx Group in a research report on Thursday, February 27th. StockNews.com downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday.

Institutional Investors Weigh In On MiMedx Group

Several hedge funds and other institutional investors have recently modified their holdings of MDXG. Barclays PLC increased its stake in MiMedx Group by 163.9% in the third quarter. Barclays PLC now owns 262,449 shares of the company's stock worth $1,550,000 after purchasing an additional 163,005 shares during the period. Principal Financial Group Inc. grew its holdings in shares of MiMedx Group by 6.3% in the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock worth $328,000 after purchasing an additional 3,292 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in MiMedx Group by 265.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock valued at $1,757,000 after buying an additional 215,995 shares in the last quarter. Fiduciary Alliance LLC bought a new stake in MiMedx Group during the 4th quarter valued at about $160,000. Finally, SG Americas Securities LLC boosted its position in MiMedx Group by 79.9% in the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock valued at $802,000 after buying an additional 37,031 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.